title: A survey of the utilization of anti-pseudomonal beta-lactam therapy in cystic fibrosis patients.
abstract: The purpose of this study was to characterize the utilization of anti-pseudomonal beta-lactam antibiotics in the treatment of acute pulmonary exacerbations (APE) among Cystic Fibrosis Foundation (CFF)-accredited care centers. An anonymous national cross-sectional survey of CFF-accredited care centers was performed using an electronic survey tool (SurveyMonkey.com®). One hundred and twenty-one of 261 centers completed the survey (46%) representing 56% (14,856/26,740) of patients in the CFF Patient Registry. One hundred and nineteen of 121 (98%) respondents reported using beta-lactams for the treatment of APE. Intermittent dosing regimens constituted 155/167 (93%) reported regimens, while extended infusions were 12/167 (7%). Ceftazidime was the most commonly utilized beta-lactam comprising 74/167 (44%) of all infusions (intermittent and extended) of which 70/74 (95%) were intermittent infusions. The majority of intermittent ceftazidime regimens (56/70; 80%) were at doses lower than CFF and European guidelines recommended doses. In conclusion, a great majority of respondents use intermittent anti-pseudomonal beta-lactam antibiotics, with over half of respondents utilizing lower than guidelines recommended doses. While this is of concern, it is not known if optimization of dosing strategies according to guidelines recommendations will result in clinical benefit.
authors.affiliation: Department of Pharmacy, Intermountain Primary Children's Medical Center, Salt Lake City, UT 84113, USA. jeffery.zobell@imail.org
authors.forename: Jeffery T
authors.initials: JT
authors.lastname: Zobell
authors.forename: David C
authors.initials: DC
authors.lastname: Young
authors.forename: C Dustin
authors.initials: CD
authors.lastname: Waters
authors.forename: Krow
authors.initials: K
authors.lastname: Ampofo
authors.forename: Jared
authors.initials: J
authors.lastname: Cash
authors.forename: Bruce C
authors.initials: BC
authors.lastname: Marshall
authors.forename: Jared
authors.initials: J
authors.lastname: Olson
authors.forename: Barbara A
authors.initials: BA
authors.lastname: Chatfield
mesh_terms: D000900:Anti-Bacterial Agents / Q000494:pharmacology / Q000627:therapeutic use*; D003430:Cross-Sectional Studies; D003550:Cystic Fibrosis / Q000188:drug therapy*; D003625:Data Collection; D018450:Disease Progression; D004363:Drug Utilization / Q000706:statistics & numerical data; D006801:Humans; D011549:Pseudomonas / Q000187:drug effects; D047090:beta-Lactams / Q000494:pharmacology / Q000627:therapeutic use*
chemical_list: D000900:Anti-Bacterial Agents; D047090:beta-Lactams